Overcoming endocrine resistance in breast cancer: Role of the PI3K and the mTOR pathways

Expert Review of Anticancer Therapy

Volumn 13, Issue 2, 2013, Pages 143-147

  Provenzano, Aaron ^a   Kurian, Sobha ^a   Abraham, Jame ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

breast cancer; endocrine resistance; mTOR; PI3K

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR INTERACTION; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TAMOXIFEN; TOR SERINE-THREONINE KINASES;

EID: 84873911892     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.173     Document Type: Article

References (22)

1. Gaughan E, Come S. Optimizing therapy for metastatic breast cancer. Curr. Breast Can. Reports 4, 30-38 (2012).
2. Boulay A, Rudloff J, Ye J et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. 11(14), 5319-5328 (2005).
3. Singletary S, Hortobagyi G, Robb G. Endocrine therapy for metastatic breast cancer. In: Advanced Therapy of Breast Disease. BC Decker, ON, Canada, 571 (2004).
4. Yamnik R, Holz M. mTOR/S6K1 and MAPK/RSK signaling pathways coordi-nately regulate estrogen receptor α serine 167 phosphorylation. FEBS Lett. 584(1), 124-128 (2009).
5. Osborne C, Shou J, Massarweh S et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for estrogen therapy resistance in breast cancer. Clin. Cancer Res. 11, 865s-870s (2005).
6. Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JM. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr. Relat. Cancer 11(4), 623-641 (2004).
7. Johnston SR, Martin LA, Head J, Smith I, Dowsett M. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J. Steroid Biochem. Mol. Biol. 95(1-5), 173-181 (2005).
8. Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 95(5), 353-361 (2003).
9. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96(12), 926-935 (2004).
10. Yue W, Fan P, Wang J, Li Y, Santen RJ. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J. Steroid Biochem. Mol. Biol. 106 (1-5), 102-110 (2007).
11. Khasraw M, Harvey S, Bell R. Hormonal resistance in breast cancer: evolving treatment strategies. Curr. Breast Can. Report. 4, 66-74 (2012).
12. Singletary S, Hortobagyi G, Robb G. Endocrine therapy for metastatic breast cancer. In: Advanced Therapy of Breast Disease. BC Decker, ON, Canada, 570 (2004).
13. Ravikumar B, Sarkar S, Davies JE et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol. Rev. 90(4), 1383-1435 (2010).
14. Samaddar JS, Gaddy V T, Duplantier J et al. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol. Cancer Ther. 7(9), 2977-2987 (2008).
15. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS ONE 4(7), e6251 (2009).
16. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin. Cancer Res. 13(24), 7271-7279 (2007).
17. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366(6), 520-529 (2012).
18. Bachelot T, Bourgier C, Cropet C et al. Randomized Phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-nega-tive metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. 30(22), 2718-2724 (2012).
19. Sanchez CG, Ma CX, Crowder RJ et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 13(2), R21 (2011).
20. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9(8), 550-562 (2009).
21. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8(8), 627-644 (2009).
22. Holmes D. PI3K pathway inhibitors approach junction. Nat. Rev. Drug Discov. 10(8), 563-564 (2011).